MindMed is focused on advancing brain health through the development of novel drug candidates, particularly leveraging the therapeutic potential of psychedelics and other innovative compounds. Their research and development pipeline encompasses a variety of therapeutic areas, including psychiatry, addiction, pain management, and neurology. MindMed's lead candidates, such as MM120 (LSD D-tartrate) and MM402 (R(-)-MDMA), have shown promising clinical benefits across multiple conditions, including anxiety disorders and autism spectrum disorder (ASD). The company employs a rigorous approach to drug development, utilizing extensive clinical data and mechanistic rationale to support their therapeutic strategies.

In addition to traditional clinical trials, MindMed is also exploring digital medicine studies to enhance treatment efficacy and patient engagement. Their clinical trials, such as those for MM-120 and MM-402, have been conducted in various locations worldwide, demonstrating a commitment to addressing unmet medical needs through innovative research methodologies. The company emphasizes the importance of a world-class team of drug developers and digital medicine experts, aiming to create effective solutions for significant brain health disorders. Through their diverse pipeline and focus on both pharmacological and digital interventions, MindMed is positioned as a leader in the evolving landscape of mental health treatment.

United States

MindMed is a clinical-stage biopharmaceutical company developing novel products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems.

Psychological Diseases

MindMed

Anxiety Disorders

<p class="font_8">Lysergide is a synthetic ergotamine belonging to the group of classic psychedelics, which acts as a partial agonist at human serotonin-2A (5-hydroxytryptamine-2A [5-HT2A]) receptors.&nbsp;</p>

MindMed

Company Details